JPRN-UMIN000003582
Completed
未知
The Observational Study of Chronic Myeloid Leukemia Patients in Chronic Phase with Resistance or Intolerance to Preceding TKI in Japan - The New Target Observational Study 2
The Japanese Society of Hematology0 sites110 target enrollmentMay 10, 2010
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- The Japanese Society of Hematology
- Enrollment
- 110
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)Patients previously treated with any investigational drug for CML. 2\)Women with confirmed or potential pregnancy, nursing mothers, and male or female patients who wish to have a child during the study period. 3\)Patients with a history of allergy to imatinib, nilotinib or dasatinib. 4\)Patients with any concomitant illness that contraindicates use of imatinib, nilotinib or dasatinib. 5\)Patients with any other condition that, in the investigator's opinion, disqualifies them for inclusion in the study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
The Observational Study of De Novo Chronic Myeloid Leukemia Patients in Chronic Phase in JapaChronic Myeloid LeukemiaJPRN-UMIN000003581The Japanese Society of Hematology500
Not yet recruiting
Not Applicable
Chronic Myeloid LeukemiaHealth Condition 1: C921- Chronic myeloid leukemia, BCR/ABL-positiveCTRI/2021/08/035398DRREETIKA RAMANATHA
Completed
Not Applicable
CML V - chronic phase Chronic Myeloid LeukaemiaeukaemiaCancerMyeloid leukaemiaISRCTN68784584niversity of Oxford (UK)800
Completed
Not Applicable
CML IV - Chronic phase chronic myeloid leukaemia/CML 2000eukaemiaCancerChronic myeloid leukaemiaISRCTN61147621Medical Research Council (MRC) (UK)800
Completed
Not Applicable
Nilotinib for Patients With Chronic Myeloid Leukemia in First Line and Any Subsequent LineChronic Myeloid LeukemiaNCT05734053Novartis Pharmaceuticals222